FUM Stock Overview
Research, develops, and sells pharmaceutical and healthcare products for sexual health. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Futura Medical plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.099 |
| 52 Week High | UK£0.46 |
| 52 Week Low | UK£0.085 |
| Beta | 1.14 |
| 1 Month Change | -12.70% |
| 3 Month Change | -67.41% |
| 1 Year Change | -72.65% |
| 3 Year Change | -68.67% |
| 5 Year Change | -3.41% |
| Change since IPO | -86.15% |
Recent News & Updates
Recent updates
Futura Medical plc (LON:FUM) Shares Slammed 48% But Getting In Cheap Might Be Difficult Regardless
Jan 31
Need To Know: Analysts Are Much More Bullish On Futura Medical plc (LON:FUM)
Sep 13We Think Futura Medical (LON:FUM) Can Easily Afford To Drive Business Growth
Apr 17Here's Why We're Not At All Concerned With Futura Medical's (LON:FUM) Cash Burn Situation
Jan 05Is Futura Medical (LON:FUM) In A Good Position To Invest In Growth?
Jul 28We Think Futura Medical (LON:FUM) Needs To Drive Business Growth Carefully
Mar 18We're Keeping An Eye On Futura Medical's (LON:FUM) Cash Burn Rate
Sep 25Here's Why We're Not Too Worried About Futura Medical's (LON:FUM) Cash Burn Situation
May 10We're Interested To See How Futura Medical (LON:FUM) Uses Its Cash Hoard To Grow
Jan 10What We Learned About Futura Medical's (LON:FUM) CEO Compensation
Dec 21
Shareholder Returns
| FUM | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 7.1% | -6.9% | -1.0% |
| 1Y | -72.7% | -9.7% | -3.0% |
Return vs Industry: FUM underperformed the UK Pharmaceuticals industry which returned -9.6% over the past year.
Return vs Market: FUM underperformed the UK Market which returned -2.8% over the past year.
Price Volatility
| FUM volatility | |
|---|---|
| FUM Average Weekly Movement | 15.2% |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: FUM's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: FUM's weekly volatility has increased from 9% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 12 | James Barder | www.futuramedical.com |
Futura Medical plc research, develops, and sells pharmaceutical and healthcare products for sexual health. Its lead product is Eroxon, a topical gel for the treatment of erectile dysfunction. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.
Futura Medical plc Fundamentals Summary
| FUM fundamental statistics | |
|---|---|
| Market cap | UK£30.08m |
| Earnings (TTM) | -UK£3.75m |
| Revenue (TTM) | UK£8.40m |
3.6x
P/S Ratio-8.0x
P/E RatioIs FUM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FUM income statement (TTM) | |
|---|---|
| Revenue | UK£8.40m |
| Cost of Revenue | UK£2.71m |
| Gross Profit | UK£5.69m |
| Other Expenses | UK£9.44m |
| Earnings | -UK£3.75m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Apr 15, 2025
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 67.70% |
| Net Profit Margin | -44.68% |
| Debt/Equity Ratio | 0% |
How did FUM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/11 22:23 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Futura Medical plc is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Navid Malik | Cavendish Historical (Cenkos Securities) |
| Francesco Gregori | Edison Investment Research |
| Sebastien Jantet | Panmure Liberum |